Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression

Molecular Therapy

Volumn 23, Issue 4, 2015, Pages 769-778

  Curran, Kevin J ^a   Seinstra, Beatrijs A ^a   Nikhamin, Yan ^a   Yeh, Raymond ^a   Usachenko, Yelena ^a   Van Leeuwen, Dayenne G ^a   Purdon, Terence ^a   Pegram, Hollie J ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FAS ANTIGEN; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P70; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; HYBRID PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DNA MODIFICATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; T LYMPHOCYTE; TH1 CELL; ANIMAL; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; METABOLISM; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; CD40 LIGAND; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MICE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84927070775     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.4     Document Type: Article

References (51)

1. Curran, KJ, Pegram, HJ and Brentjens, RJ (2012). Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 14: 405-415.
2. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19- targeted T cells rapidly induce molecular remissions in adults with chemotherapyrefractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
3. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
4. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
5. Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6: 224ra25.
6. Vesely, MD, Kershaw, MH, Schreiber, RD and Smyth, MJ (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
7. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
8. Armitage, RJ, Fanslow, WC, Strockbine, L, Sato, TA, Clifford, KN, Macduff, BM et al. (1992). Molecular and biological characterization of a murine ligand for CD40. Nature 357: 80-82.
9. Schönbeck, U and Libby, P (2001). The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58: 4-43.
10. Uckun, FM, Gajl-Peczalska, K, Myers, DE, Jaszcz, W, Haissig, S and Ledbetter, JA (1990). Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76: 2449-2456.
11. Gruss, HJ, Ulrich, D, Braddy, S, Armitage, RJ and Dower, SK (1995). Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 25: 2083-2089.
12. Zong, YS, Lin, H, Choy, DT, Sham, JS, Wei, W, Chan, KH et al. (1991). Nasopharyngeal carcinoma and lymphoinfiltration. Oncology 48: 290-296.
13. Lollini, PL, Landuzzi, L, Frabetti, F, Rossi, I, Nicoletti, G, Scotlandi, K et al. (1998). Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin Cancer Res 4: 1843-1849.
14. van den Oord, JJ, Maes, A, Stas, M, Nuyts, J, Battocchio, S, Kasran, A et al. (1996). CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 149: 1953-1961.
15. Wingett, DG, Vestal, RE, Forcier, K, Hadjokas, N and Nielson, CP (1998). CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 50: 27-36.
16. Ciaravino, G, Bhat, M, Manbeian, CA and Teng, NN (2004). Differential expression of CD40 and CD95 in ovarian carcinoma. Eur J Gynaecol Oncol 25: 27-32.
17. Altenburg, A, Baldus, SE, Smola, H, Pfister, H and Hess, S (1999). CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFNgamma. J Immunol 162: 4140-4147.
18. Cella, M, Scheidegger, D, Palmer-Lehmann, K, Lane, P, Lanzavecchia, A and Alber, G (1996). Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747-752.
19. Clarke, SR (2000). The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukoc Biol 67: 607-614.
20. Cayabyab, M, Phillips, JH and Lanier, LL (1994). CD40 preferentially costimulates activation of CD4+ T lymphocytes. J Immunol 152: 1523-1531.
21. Peng, X, Kasran, A, Warmerdam, PA, de Boer, M and Ceuppens, JL (1996). Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol 26: 1621-1627.
22. Bhadra, R, Gigley, JP and Khan, IA (2011). Cutting edge: CD40-CD40 ligand pathway plays a critical CD8-intrinsic and -extrinsic role during rescue of exhausted CD8 T cells. J Immunol 187: 4421-4425.
23. Bourgeois, C, Rocha, B and Tanchot, C (2002). A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297: 2060-2063.
24. Khong, A, Nelson, DJ, Nowak, AK, Lake, RA and Robinson, BW (2012). The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 31: 246-266.
25. Vonderheide, RH and Glennie, MJ (2013). Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19: 1035-1043.
26. Wierda, WG, Cantwell, MJ, Woods, SJ, Rassenti, LZ, Prussak, CE and Kipps, TJ (2000). CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924.
27. Brentjens, RJ, Latouche, JB, Santos, E, Marti, F, Gong, MC, Lyddane, C et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9: 279-286.
28. Frentsch, M, Stark, R, Matzmohr, N, Meier, S, Durlanik, S, Schulz, AR et al. (2013). CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood 122: 405-412.
29. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
30. Kochenderfer, JN, Dudley, ME, Kassim, SH, Somerville, RP, Carpenter, RO, Stetler-Stevenson, M et al. (2014). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol pii:JCO.2014.56.2025.
31. Stephan, MT, Ponomarev, V, Brentjens, RJ, Chang, AH, Dobrenkov, KV, Heller, G et al. (2007). T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13: 1440-1449.
32. Greaves, P and Gribben, JG (2013). The role of B7 family molecules in hematologic malignancy. Blood 121: 734-744.
33. Geijtenbeek, TB, van Kooyk, Y, van Vliet, SJ, Renes, MH, Raymakers, RA and Figdor, CG (1999). High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. Blood 94: 754-764.
34. Rieux-Laucat, F, Le Deist, F, Hivroz, C, Roberts, IA, Debatin, KM, Fischer, A et al. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349.
35. Schultze, JL, Cardoso, AA, Freeman, GJ, Seamon, MJ, Daley, J, Pinkus, GS et al. (1995). Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92: 8200-8204.
36. Schattner, EJ, Mascarenhas, J, Bishop, J, Yoo, DH, Chadburn, A, Crow, MK et al. (1996). CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood 88: 1375-1382.
37. O'Neill, DW, Adams, S and Bhardwaj, N (2004). Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104: 2235-2246.
38. Higham, EM, Wittrup, KD and Chen, J (2010). Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol 184: 3394-3400.
39. Pegram, HJ, Lee, JC, Hayman, EG, Imperato, GH, Tedder, TF, Sadelain, M et al. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119: 4133-4141.
40. Trinchieri, G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
41. Laurin, D, Marin, V, Biagi, E, Pizzitola, I, Agostoni, V, Gallot, G et al. (2013). Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor. J Immunother 36: 181-189.
42. Bossen, C, Ingold, K, Tardivel, A, Bodmer, JL, Gaide, O, Hertig, S et al. (2006). Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281: 13964-13971.
43. Brown, MP, Topham, DJ, Sangster, MY, Zhao, J, Flynn, KJ, Surman, SL et al. (1998). Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 4: 1253-1260.
44. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
45. Ghani, K, Wang, X, de Campos-Lima, PO, Olszewska, M, Kamen, A, Rivière, I et al. (2009). Efficient human hematopoietic cell transduction using RD114- and GALVpseudotyped retroviral vectors produced in suspension and serum-free media. Hum Gene Ther 20: 966-974.
46. Ratzinger, G, Reagan, JL, Heller, G, Busam, KJ and Young, JW (2003). Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 101: 1422-1429.
47. Rivière, I, Brose, K and Mulligan, RC (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92: 6733-6737.
48. Brentjens, RJ, Santos, E, Nikhamin, Y, Yeh, R, Matsushita, M, La Perle, K et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13 (18 Pt 1): 5426-5435.
49. Gong, MC, Latouche, JB, Krause, A, Heston, WD, Bander, NH and Sadelain, M (1999). Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostatespecific membrane antigen. Neoplasia 1: 123-127.
50. Santos, EB, Yeh, R, Lee, J, Nikhamin, Y, Punzalan, B, Punzalan, B et al. (2009). Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med 15: 338-344.
51. Quintás-Cardama, A, Yeh, RK, Hollyman, D, Stefanski, J, Taylor, C, Nikhamin, Y et al. (2007). Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther 18: 1253-1260.